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Abstract 
Objective: The aims of the present study were to determine the proportions of hepatitis 
B surface antigen (HBsAg)-positive and anti-hepatitis C virus (HCV)-positive patients, 
and identify the characteristics that influenced referral to a hepatologist. 
Methods: The present study included patients who were positive for HBsAg (n = 153) or 
anti-HCV (n = 574); their viral status was tested by non-hepatologists between January 
2008 to December 2012. We performed a multivariate analysis to investigate the factors 
associated with the referral of patients to hepatologists. 
Results: The rates of hepatitis B virus (HBV) and the percentage of suspected HCV 
carriers at the hospital were 1.4% and 3.5%, respectively. Among the 727 patients who 
were seropositive for HBV or HCV, 107 (14.7%) were referred to a hepatologist. A 
multivariate analysis to investigate the factors contributing to referral revealed that (i) 
an alanine aminotransferase (ALT) level of >30 IU/L (odds ratio [OR], 3.24; 95% 
confidence interval [CI], 2.10–5.03; P < 0.001); (ii) undergoing testing at an internal 
medicine department (OR, 2.79; 95% CI, 1.80–4.38; P < 0.001); and (iii) HBsAg-positivity 
(OR, 2.22; 95% CI, 1.35–3.61; P = 0.002) were factors that significantly influenced 
referral. 
Conclusions: Hepatologists must educate non-hepatologists, especially non-internists, to 
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promote the referral of hepatitis-virus carriers, especially HCV carriers, even in patients 
with ALT levels of <30 IU/L. 
Key words: hepatitis virus carriers, medical collaboration, non-hepatologist, HBV, HCV 
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Introduction 
The prevalence rates of hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections in Japan are estimated to be 0.71% and 0.63%, respectively (1). As HBV and 
HCV are major causes of cirrhosis, liver failure, and liver cancer, the initiation of 
appropriate treatment is important for achieving a better prognosis (2, 3). 
Although recent advances in antiviral therapy have caused dramatic improvements 
in the treatment of hepatitis virus infection, only a minority of HBV- or HCV-infected 
patients receive treatment due to multiple barriers, including patient factors (e.g., 
ongoing drug or alcohol abuse or psychiatric contraindications), provider factors (e.g., the 
physician’s lack of knowledge or a reluctance to treat past drug abusers), and system 
factors (e.g., referral-associated delays or a lack of funds) (4-12). In addition, treated 
patients are significantly more likely to be referred to a hepatologist, in comparison to 
untreated patients (11). A previous study indicated that developing collaboration 
between specialists and primary care providers had the potential to improve the quality 
of HCV care (13). However, little attention has been paid to the actual collaboration 
between hepatologists and non-hepatologists in the hospital setting. 
The Hakujyuji Hospital provides health care for an almost exclusively urban 
population of 1,500,000 inhabitants. The medical departments within the hospital 
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function independently. The aims of the present study were to determine the proportion 
of hepatitis B surface antigen (HBsAg)-positive and anti-HCV-positive patients, and 
identify the characteristics of the patients who were referred (or not referred) to 
hepatologists in order to provide information for future interventions and to improve the 
rate of referral. 
 
Materials and Methods 
This retrospective study included the patients who tested positive for HBsAg and/or 
anti-HCV at our hospital over the 5 years from January 2008 to December 2012. Patients 
who were both HBsAg and anti-HCV-positive were excluded from the assessment of the 
effect of the virus type on referral. Patients who were already being tested and managed 
by hepatologists were excluded from the study. Ethical approval was obtained from the 
ethics committee of the hospital. 
HBsAg was detected using the Architect-HBsAg QT assay (Abbott Laboratories, 
Tokyo, Japan); the cutoff level was 0.05 IU/mL. Anti-HCV was detected using the 
Architect-HCV assay (Abbott Laboratories); the cutoff point was a signal to cut-off ratio 
of 1.0. 
The patients were classified into two groups: those who were referred to 
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hepatologists (referrals) and those who were not referred to hepatologists (non-referrals). 
We retrospectively collected the following 12 characteristics of these patients: sex, age 
on the day of the test, the department in which the viral status was tested (internal 
medicine or a non-internal medicine department), the physician’s years of experience on 
the date of the test, the presence of a family doctor (present or absent), platelet count, 
prothrombin time (%), viral hepatitis markers (HBsAg and anti-HCV), and the serum 
levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-
glutamyl transferase (GGT), and total bilirubin. 
The internal medicine departments at our hospital included Diabetes, Neurology, 
Gastroenterology, Nephrology, Cardiology, Hematology, and Endocrinology. The non-
internal medicine departments included General and Gastroenterological Surgery, 
Breast Surgical Oncology, Orthopedic Surgery, Plastic Reconstructive Surgery, 
Neurosurgery, Urology, Ophthalmology, Oral Surgery, Physical Medicine, and 
Rehabilitation. The presence of a family doctor was determined by reviewing the patients’ 
electronic medical records; “present” was defined by management of the patient’s hepatic 
condition at another clinic, and absent was defined by the absence of another location of 
management. The most recent blood test result at the time of viral testing was included 
in the analysis. 
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In addition, we used the aforementioned data to create a decision tree from the 
factors that were found to affect referral to a hepatologist and performed a data mining 
analysis to further determine the reasons for referral. 
The differences in the baseline characteristics of the groups were analyzed using 
Wilcoxon’s signed test for continuous variables and Pearson’s chi-squared test for 
categorical variables. A multivariate analysis was performed using stepwise logistic 
regression models. P values <0.05 were considered to indicate statistical significance. All 
of the analyses were performed using the JMP software program (version 10; SAS 
Institute, Cary, NC). 
 
Results 
The prevalence of HBsAg or anti-HCV seropositivity 
Among the 11,823 patients who were tested for HBsAg, 163 (1.4%) tested positive. 
Among the 11,320 patients who were tested for anti-HCV, 584 (5.2%) tested positive. Ten 
patients were positive for both HBsAg and anti-HCV (Figure 1). 
 
The referral status and the characteristics of the seropositive patients 
The overall, referral rate for seropositive patients was 14.7% (107/727). The referral 
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rates for HBsAg-positive and anti-HCV-positive patients were 20.9% (32/153) and 13.1% 
(75/574), respectively (Figures 1, 2). Among the 75 anti-HCV-positive patients who were 
referred to a hepatologist, 47 patients whose general condition could be treated with 
antiviral therapy or who did not have liver cancer or cirrhosis underwent an HCV RNA 
test; HCV RNA was detected in the serum of 32 patients (68.1%) by a polymerase chain 
reaction. Eighteen of these 32 (56.3%) patients were infected with non-1 HCV genotypes. 
The patients in the referral group were significantly younger than those in the non-
referral group (Table 1). The rate of referral from internal medicine departments was 
significantly higher than that from non-internal medicine departments. The serum AST, 
ALT, and GGT levels were significantly higher and the platelet count was significantly 
lower in the referral group. A significantly greater number of patients in the referral 
group were HBsAg-positive, while significantly fewer were anti-HCV-positive. 
The multivariate analysis showed that hepatitis virus-positive patients were 
referred to a hepatologist from a non-hepatologist based on the following factors: an ALT 
level of ≥31 IU/L (odds ratio [OR], 3.24; 95% confidence interval [CI], 2.10–5.03; P < 
0.001), undergoing testing in an internal medicine department (OR, 2.79; 95% CI, 1.80–
4.38; P < 0.001), or HBsAg positivity (OR, 2.22; 95% CI, 1.35–3.61; P = 0.002) (Table 2 
and Figure 2). 
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The data mining analysis 
A data mining analysis was performed to assess the reasons why the patients were 
referred to a hepatologist. The results are shown in Figure 3. This analysis classified 
four subgroups based on the three factors that influenced the decision to refer a patient 
to a hepatologist. The serum ALT value was selected as the best influential factor. 
Patients with an ALT level of ≥31 IU/L had a higher referral rate than those with an ALT 
level of <31 IU/L (25.7% vs. 9.9%, P < 0.001). Among the patients with an ALT level of 
≥31 IU/L, the type of department was strongly associated with referral. The referral rate 
of patients who underwent testing at an internal medicine department was higher than 
that of patients who underwent testing at a non-internal medicine department (38.5% 
vs. 12.8%, P < 0.001). In patients with an ALT level of <31 IU/L, the type of the hepatitis 
virus was strongly associated with referral. HBsAg-positive patients had a higher 
referral rate than those who were anti-HCV-positive (17.8% vs. 7.5%, P = 0.001). 
Furthermore, among the four subgroups, most patients had an ALT level of <31 IU/L, 
and the anti-HCV-positive group had the lowest referral rate. 
 
Discussion 
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Our study showed that among the patients who were tested for the hepatitis virus 
by a non-hepatologist at our hospital, 1.4% were HBsAg-positive and 5.2% were anti-
HCV-positive. The true rate of HCV positivity among the anti-HCV-positive referrals was 
3.5%, because HCV RNA was detected in 68.1% of these patients—which is similar to 
the rate reported in previous studies (14, 15). However, this result should be interpreted 
carefully, as there may be selective bias since only treatable patients were tested for HCV 
RNA. In the present study, both the HBsAg-positive rate and the estimated HCV carrier 
rate were higher than the recently reported prevalence rates in Japan of 0.71% and 
0.63%, respectively (1). One potential reason for this difference may be the high 
proportion of elderly patients in the study, particularly because the prevalence of HCV 
was shown to increase with age in reports from Japan (1, 15). Another potential reason 
is the area. In the Kyushu area, in which our hospital is located, the HBV and HCV 
carrier rates are high (0.96% and 0.80%, respectively) in comparison to the rest of Japan 
(1). Moreover, 56.3% of the anti-HCV-positive patients at our hospital were infected with 
non-1 HCV genotypes, which is higher than the estimated 30% in the entire Japanese 
population (1, 15). As intravenous drug abuse and tattoos are the major routes of non-
genotype 1 HCV transmission in Japan (16, 17), the high prevalence of hepatitis virus 
at our hospital was likely associated with regional variations in these behaviors. 
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Despite the high prevalence of hepatitis virus infection, at only 14.7%, the rate of 
referral to hepatologists was suboptimal. Our data demonstrated a greater tendency for 
referral if the patient had an ALT level of ≥31 IU/L, underwent testing at an internal 
medicine department, or was HBsAg-positive. 
Among the three factors that were analyzed, the factor that most strongly influenced 
referral to a hepatologist was the ALT level. Regarding the high rate of referrals in 
patients with an ALT level of ≥31 IU/L, the upper limit of normal for ALT at our hospital 
is 30 IU/L—at this cutoff point, the value is flagged in red in electronic medical records 
to attract the health care providers’ attention. Consequently, non-hepatologists were 
more likely to refer patients to hepatologists due to high ALT values. Moreover, hepatitis 
virus carriers with normal ALT levels have a higher risk of cirrhosis and liver cancer in 
comparison to non-carriers (18-20). Thus, physicians need to be aware that referral to a 
hepatologist is necessary, even for patients with normal ALT levels. 
In the subgroup of patients with an ALT level of ≥31 IU/L, the referral rate among 
patients who underwent testing in an internal medicine department was higher than 
that among patients underwent testing in a non-internal medicine department. This 
may indicate the different reasons for testing patients for hepatitis virus. For instance, 
internists may tend to perform hepatitis viral testing to identify the cause of liver 
12 
 
dysfunction, whereas non-internists may be more likely to perform these tests for 
preoperative surveillance. This gap in perception by internists and non-internists might 
have influenced the referral rate. 
The referral rate of patients with an ALT level of <31 IU/L, was higher for patients 
who were HBsAg-positive. It is thought that the physicians were more careful about the 
management of HBV carriers, because there is a general agreement that the infectious 
capacity of HBV is stronger than that of HCV. In addition, HBV often causes serious 
clinical conditions, such as severe hepatitis (21-23). In the present study, there was a 
similar result in cases with a normal ALT level (24, 25). Furthermore, this result showed 
importance of measures for identifying anti-HCV-positive patients, who have a low 
referral rate. Given the recent and remarkable progress in the treatment of HCV, these 
measures will become increasingly necessary in order to identify hepatitis virus carriers 
in hospitals and determine an appropriate treatment strategy. 
The perceived barriers to referral to hepatologists are significantly associated with 
the physician’s knowledge (10). The findings of the current study suggest that among 
non-hepatologists, there is a gap in the knowledge of viral hepatitis between internists 
and non-internists. In particular, there was disparity in recognizing HCV infection in 
patients with a normal ALT level. 
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The present study is associated with some limitations. First, this study was 
retrospective in nature and was conducted at a single institution in Japan. Thus, the 
results may not be generalizable to other patient settings. Second, the reason for referral 
(or a lack of referral) by chief doctors to hepatologists was unclear. To improve the 
referral rate, these reasons should be elucidated. 
In conclusion, to improve the current low rate of referral of hepatitis virus carriers, 
hepatologists should encourage and instruct non-hepatologists, especially non-internists 
to refer patients with hepatitis virus, especially those who are anti-HCV-positive, to a 
hepatologist—even if the patient’s ALT level is normal. 
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Table 1 Characteristics of the patients with hepatitis virus between those with and without the 
consultation to a hepatologist 
Factor 
Consultation  
(n=107) 
No consultation  
(n=620) 
P-value 
Sex (Male/Female) 71/36 364/256 0.136 
Age 62 (21-95) 74 (17-99) <0.001 
Department (Internal Medicine/others) 70/37 248/372 <0.001 
The years of experience of the 
physician 
15 (3-51) 16 (3-51) 0.365 
Family doctor (+/-) 28/79 186/434 0.422 
HBsAg/anti-HCV 32/75 121/499 0.015 
AST (IU/L) 35 (12-1036) 25 (9-5000) <0.001 
ALT (IU/L) 34 (6-2530) 20 (2-2635) <0.001 
GGT (IU/L) 44 (10-839) 25 (5-867) <0.001 
Total Bilirubin (mg/dL) 0.75 (0.3-28.9) 0.7 (0.1-7.0) 0.007 
Platelet (×104/μg) 19.8 (3.21-65.3) 22.0 (2.88-57.8) 0.009 
PT (%) 89.5 (9.1-156.6) 89.1 (9.8-184.3) 0.245 
 
Table 2 Multivariate analysis of factors associated with a consultation with a hepatologist from 
non-hepatologist for the patients with hepatitis B surface antigen (HBsAg)-positive or anti-
hepatitis C virus (HCV)-positive 
Factor 
Multivariate analysis 
OR (95% CI) P-value 
ALT ≥31 IU/L 3.24 (2.10-5.03) <0.001 
Department (Internal Medicine) 2.79 (1.80-4.38) <0.001 
HBsAg positive 2.22 (1.35-3.61) 0.002 
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Figure Legends 
Figure 1. A flow chart of patients included in this retrospective study 
 
HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus 
 
Figure 2. The referral rate of hepatitis virus-positive patients to a hepatologist from a 
non-hepatologist based on an alanine aminotransferase (ALT) level of ≥31 IU/L, 
undergoing viral testing at an internal medicine department, and hepatitis B surface 
antigen (HBsAg) or anti-hepatitis C virus (HCV) positivity. 
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Figure 3. A decision tree model of the factors associated with referral to a hepatologist.  
 
The rectangles indicate the variables that were used to differentiate the patients. The 
pie charts indicate the referral rate to a hepatologist for each group. The groups were 
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further classified into four subgroups by the three factors. The serum ALT value was 
selected as the factor that had the greatest influence on referral. Patients with an ALT 
level of ≥31 IU/L had a higher referral rate than those with an ALT level of <31 IU/L. In 
patients with an ALT level of ≥31 IU/L, the clinical department in which the patient 
underwent testing was strongly associated with the referral rate. Patients who 
underwent testing in an internal medicine department had a higher referral rate. In 
patients with an ALT level of <31 IU/L, the type of hepatitis virus was strongly 
associated with the referral rate. HBsAg-positive patients had a higher referral rate than 
anti-HCV-positive patients. 
ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HCV, hepatitis C 
virus; HBV, hepatitis B virus 
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